Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients

Table 4

The lymphocyte counts of COVID-19 patients before and after TCZ treatment (/μL).

Case no.	Before TCZ therapy	After TCZ therapy							Clinical outcomes
		Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
1	330	260	240			180			Death
2	680	910	1110	1140	1590			2400	Clinical improvement
3	1220		780		950			1160	Clinical improvement
4	1090	870			890				Clinical improvement
5	1270	950			1740				Clinical improvement
6	780	690				1030		1070	Clinical improvement
7	940	547		1180				1510	Clinical improvement
8	1070	1020				1980			Clinical improvement
9	1030				1020				Clinical improvement
10	660	700	570	640		220	270	490	Death
11	1150	900						1040	Clinical improvement
12	1470		1089		1180			1598	Clinical improvement
13	1280	1420		1580	1690		1670		Clinical aggravation

The normal value of lymphocyte counts ranges from 1100 to 3200/μL.